Kovo HealthTech Corporation provided revenue guidance for the year of 2022. In its initial 2022 Guidance, the Company is anticipating Pro Forma Revenues of CAD 15,000,000 (USD 12,000,000), a 30% increase in year-over-year organic growth excluding additional acquisitions in 2022.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.025 CAD | -.--% | -.--% | -16.67% |
1st Jan change | Capi. | |
---|---|---|
-16.67% | 1.05M | |
-9.49% | 28.16B | |
+25.35% | 8.33B | |
+33.25% | 4.39B | |
-35.85% | 2.43B | |
-9.44% | 1.6B | |
-13.39% | 1.5B | |
-32.84% | 1.15B | |
+7.80% | 964M | |
-37.56% | 872M |
- Stock Market
- Equities
- KOVO Stock
- News Kovo HealthTech Corporation
- Kovo HealthTech Corporation Provides Revenue Guidance for the Year of 2022